Hope Rugo, MD, director of the breast oncology clinical trials program at the University of California at San Francisco, discusses guidelines for the treatment of cancer.
Transcript:
In your experience, are value frameworks, such as those developed by NCCN and ASCO, being implemented in clinical practice?
I think value frameworks are being implemented in practice. I think people use guidelines internationally and that they find them very helpful and important.
Interestingly, sometimes people are so concrete with the guidelines [that] it results in more peer-to-peer reviews for patients because they’ll say, “Well you know, you can’t get that drug because it said that they only had 2 lines of therapy there and that patient had 3 lines.” And then we’re like, “Well, it’s not going to make that big of a difference.” Or, they only had 1 and it said the trial was only done in patients that had 2 lines of therapy. You can become very, very concrete in terms of how you interpret those guidelines.
Overall, I think guidelines are important, they give a consensus approach, they take the literature and best practices and provide that information for busy practitioners who are treating many different cancers and provide them essentially with back up.
Also, the guidelines generally provide patient-friendly forms of their guideline information, and that’s incredibly important. We want our patients to be educated as much as possible about what options exist, and it allows patients potentially to participate more in shared decision-making, and to understand when the decisions don’t fit those guidelines.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.